BioSpace News Archive

HyperMed Imaging, Inc. Announces CE Mark for New HyperView™ Product

European Approval for Groundbreaking Imaging Technology

April 2, 2018

·

3 min read

BioForest

April AARP Bulletin Special Report: US Government losing $1,000 to health fraud per every Medicare beneficiary; Losses are “massive,” Attorney General Jeff Sessions tells AARP

Roughly $60 billion is lost each year to Medicare fraud or waste, equal to 10 cents of every dollar budgeted for the program.

April 2, 2018

·

3 min read

Genetown

CSA Medical Supports Esophageal Cancer Awareness Month

April is Esophageal Cancer Awareness month. CSA Medical is committed to raising awareness of Esophageal Cancer and the importance of early diagnosis and treatment.

April 2, 2018

·

2 min read

Business

TSO3 Appoints Dr. Douglas Dieter to its Board of Directors

TSO3 Inc. announced that it has appointed Dr. Doug Dieter to its board of directors.

April 2, 2018

·

2 min read

Deals

BioMatrix Specialty Pharmacy Acquires Decillion Healthcare Extending Footprint In Midwestern States

BioMatrix Specialty Pharmacy announced that it has acquired Decillion Healthcare, near Columbus, Ohio effective March 13, 2018.

April 2, 2018

·

1 min read

Genetown

A Recipe for Health Success: Community Servings’ Medically Tailored Meal Delivery Service Associated with Reduced Costs for High Utilizers of Health Care

A medically tailored meal delivery service provided by Community Servings to homebound and critically or chronically ill individuals was associated with a 16 percent net reduction in health care costs, according to a new study published in the April issue of the journal Health Affairs.

April 2, 2018

·

4 min read

Drug Development

Cerus’ RedeS Phase 3 Red Blood Cell Study Expands Into the Continental U.S.

RedeS is a Phase 3 study designed to evaluate the safety and efficacy of INTERCEPT Blood Systems for Red Blood Cells (RBCs) compared to conventional RBCs in regions impacted by the Zika virus.

April 2, 2018

·

4 min read

Biotech Beach

NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination With Capecitabine or Paclitaxel as Treatment Options for Patients With Breast Cancer Brain Metastases

The NCCN designated NERLYNX in combination with capecitabine as a category 2A treatment option and NERLYNX in combination with paclitaxel as a category 2B treatment option.

April 2, 2018

·

6 min read

Business

Praxair Announces First Quarter 2018 Earnings and Conference Call Schedule

Praxair, Inc. (NYSE:PX) will release its first quarter 2018 financial results on Thursday, April 26, 2018, before the market opens and will webcast its conference call at 11:00 a.m. ET that morning.

April 2, 2018

·

1 min read

Business

Novus Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update

In 2017, completed merger with Tokai Pharmaceuticals, Inc. and embarked on a mission to develop a novel, first-in-class treatment option for otitis media.

April 2, 2018

·

7 min read